相似文献
1
VTE in ICU: Lessons from COVID-19.重症监护病房中的静脉血栓栓塞症：来自新型冠状病毒肺炎的经验教训
Intensive Care Res. 2023;3(1):92-94. doi: 10.1007/s44231-022-00016-1. Epub 2022 Oct 27.
2
Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study.COVID-19 患者静脉血栓栓塞症及其预测模型：一项多中心队列研究。
BMC Infect Dis. 2022 May 13;22(1):462. doi: 10.1186/s12879-022-07421-3.
3
Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis.与非COVID-19队列相比，COVID-19患者的静脉血栓栓塞：一项系统评价与荟萃分析
J Clin Med. 2021 Oct 25;10(21):4925. doi: 10.3390/jcm10214925.
4
The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients.COVID-19 重症患者与非 COVID 重症患者相比，静脉血栓栓塞症的发生率。
Ir J Med Sci. 2021 Nov;190(4):1317-1320. doi: 10.1007/s11845-020-02503-0. Epub 2021 Jan 7.
5
Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes.重症 COVID-19 患者静脉血栓栓塞症的患病率、危险因素及抗凝药物剂量与预后的关系
J Crit Care Med (Targu Mures). 2022 Nov 12;8(4):249-258. doi: 10.2478/jccm-2022-0023. eCollection 2022 Oct.
6
High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study.新冠病毒肺炎患者中出血和动脉血栓形成的高发生率：沙特多中心研究
Thromb J. 2021 Mar 3;19(1):13. doi: 10.1186/s12959-021-00265-y.
7
Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis.与非COVID-19队列相比，COVID-19患者的静脉血栓栓塞：一项荟萃分析的系统评价
Vascul Pharmacol. 2021 Aug;139:106882. doi: 10.1016/j.vph.2021.106882. Epub 2021 Jun 2.
8
Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients.住院COVID-19患者静脉血栓栓塞或死亡的患病率及预测因素
Thromb Haemost. 2021 Aug;121(8):1043-1053. doi: 10.1055/a-1366-9656. Epub 2022 Mar 11.
9
Incidence of COVID-19-Associated Venous Thromboembolism Among Hospitalized Patients in McAllen, Texas, USA, in Late 2021.2021年末美国得克萨斯州麦卡伦市住院患者中与新冠病毒疾病相关的静脉血栓栓塞症发病率
Cureus. 2022 Mar 17;14(3):e23270. doi: 10.7759/cureus.23270. eCollection 2022 Mar.
10
Thrombosis and Bleeding After Implementation of an Intermediate-Dose Prophylactic Anticoagulation Protocol in ICU Patients With COVID-19: A Multicenter Screening Study.在 COVID-19 重症监护病房患者中实施中等剂量预防性抗凝方案后的血栓形成与出血：一项多中心筛查研究
J Intensive Care Med. 2022 Apr;37(4):480-490. doi: 10.1177/08850666211051960. Epub 2021 Nov 25.
本文引用的文献
1
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study.在美国 546656 名住院 COVID-19 患者中，血栓形成和出血事件、死亡率和抗凝剂的使用：一项回顾性队列研究。
J Thromb Thrombolysis. 2022 May;53(4):766-776. doi: 10.1007/s11239-022-02644-2. Epub 2022 Apr 30.
2
Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report.COVID-19 患者的血栓预防：对 CHEST 指南和专家小组报告的简要更新。
Chest. 2022 Jul;162(1):213-225. doi: 10.1016/j.chest.2022.02.006. Epub 2022 Feb 12.
3
Future pandemics: failing to prepare means preparing to fail.未来的大流行病：不做准备就意味着准备失败。
Lancet Respir Med. 2022 Mar;10(3):221-222. doi: 10.1016/S2213-2600(22)00056-X. Epub 2022 Feb 10.
4
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.肝素与 SARS-CoV-2：多种病理生理学关联。
Viruses. 2021 Dec 11;13(12):2486. doi: 10.3390/v13122486.
5
Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies.严重 COVID-19 患者静脉血栓栓塞的风险因素：21 项研究的研究水平荟萃分析。
Int J Environ Res Public Health. 2021 Dec 8;18(24):12944. doi: 10.3390/ijerph182412944.
6
Gaining Insights into Asthma-related COVID-19 Risk.深入了解与哮喘相关的新冠病毒疾病风险。
Am J Respir Crit Care Med. 2022 Jan 1;205(1):1-2. doi: 10.1164/rccm.202111-2473ED.
7
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
Zotero 插件